Drug Profile
Anti-IL-23 monoclonal antibody - Merck
Latest Information Update: 02 Oct 2021
Price :
$50
*
At a glance
- Originator Schering-Plough
- Developer Merck & Co
- Class Monoclonal antibodies
- Mechanism of Action Interleukin 23 inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Inflammation
Most Recent Events
- 08 Aug 2011 No development reported - Phase-I for Inflammation in USA (Parenteral)
- 04 Nov 2009 Schering-Plough combines with Merck & Co and retains the name Merck & Co
- 01 Dec 2008 Phase-I clinical trials in Inflammation in USA (Parenteral)